Journey Medical (DERM)
(Delayed Data from NSDQ)
$5.33 USD
-0.07 (-1.30%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $5.40 +0.07 (1.31%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Brokerage Reports
[DERM]
Reports for Purchase
Showing records 41 - 47 ( 47 total )
Industry: Medical - Drugs
Raising Price Target to $22 as Best Base Scenario for Lebrikizumab Plays Out
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Lebrikizumab Takes Center Stage; Thoughts Ahead of TREBLE 2 Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
The Tortoise Shows Some Giddy-Up: Qbrexza Comes Out Ahead in 4Q
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Slides Reviewing Initiations on Dermatology and Endocrinology
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical - Drugs
Cordially invites you to a Coverage Launch Teach-In
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical - Drugs
Launching Coverage
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical - Drugs
Our Proprietary Survey Says Don''t Sweat Qbrexza Launch; Initiate at Buy With $13 Price Target
Provider: H.C. Wainwright & Co., Inc.